FY2026 Earnings Estimate for LGND Issued By HC Wainwright

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) – Stock analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Ligand Pharmaceuticals in a note issued to investors on Wednesday, December 10th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings of $4.33 per share for the year, up from their prior forecast of $1.70. HC Wainwright currently has a “Buy” rating and a $231.00 price target on the stock. The consensus estimate for Ligand Pharmaceuticals’ current full-year earnings is $1.73 per share. HC Wainwright also issued estimates for Ligand Pharmaceuticals’ FY2027 earnings at $6.30 EPS.

Ligand Pharmaceuticals (NASDAQ:LGND) last issued its earnings results on Thursday, November 6th. The biotechnology company reported $3.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $1.13. The firm had revenue of $86.89 million during the quarter, compared to analysts’ expectations of $58.71 million. Ligand Pharmaceuticals had a net margin of 19.34% and a return on equity of 5.71%. The firm’s revenue for the quarter was up 123.0% compared to the same quarter last year. During the same period last year, the firm posted $1.84 earnings per share. Ligand Pharmaceuticals has set its FY 2025 guidance at 7.400-7.650 EPS.

Several other brokerages also recently commented on LGND. Stifel Nicolaus upped their target price on Ligand Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Wednesday. Citigroup assumed coverage on shares of Ligand Pharmaceuticals in a report on Tuesday. They issued a “buy” rating and a $270.00 target price for the company. Benchmark boosted their price target on shares of Ligand Pharmaceuticals from $175.00 to $220.00 and gave the company a “buy” rating in a report on Friday, November 7th. Royal Bank Of Canada raised their price objective on shares of Ligand Pharmaceuticals from $234.00 to $235.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Oppenheimer lifted their price objective on shares of Ligand Pharmaceuticals from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, November 3rd. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Ligand Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $228.00.

Ligand Pharmaceuticals Stock Performance

LGND opened at $189.55 on Friday. The company has a quick ratio of 24.30, a current ratio of 24.69 and a debt-to-equity ratio of 0.47. The firm has a market cap of $3.73 billion, a PE ratio of 91.57 and a beta of 0.99. The business has a fifty day simple moving average of $192.43 and a 200-day simple moving average of $157.67. Ligand Pharmaceuticals has a fifty-two week low of $93.58 and a fifty-two week high of $212.49.

Institutional Investors Weigh In On Ligand Pharmaceuticals

Several institutional investors have recently made changes to their positions in LGND. Ashton Thomas Private Wealth LLC raised its position in Ligand Pharmaceuticals by 2.9% during the third quarter. Ashton Thomas Private Wealth LLC now owns 2,014 shares of the biotechnology company’s stock valued at $357,000 after acquiring an additional 56 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Ligand Pharmaceuticals by 12.3% during the 3rd quarter. GAMMA Investing LLC now owns 575 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 63 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Ligand Pharmaceuticals by 31.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 271 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 65 shares during the last quarter. CIBC Private Wealth Group LLC increased its position in Ligand Pharmaceuticals by 86.3% during the third quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company’s stock worth $26,000 after buying an additional 69 shares during the last quarter. Finally, Amalgamated Bank raised its holdings in Ligand Pharmaceuticals by 1.6% during the second quarter. Amalgamated Bank now owns 5,446 shares of the biotechnology company’s stock valued at $619,000 after buying an additional 86 shares in the last quarter. 91.28% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Ligand Pharmaceuticals

In other Ligand Pharmaceuticals news, Director Jason Aryeh sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 23rd. The stock was sold at an average price of $170.81, for a total value of $1,708,100.00. Following the transaction, the director owned 69,289 shares in the company, valued at $11,835,254.09. The trade was a 12.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director John W. Kozarich sold 467 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $195.84, for a total value of $91,457.28. Following the completion of the transaction, the director directly owned 44,121 shares in the company, valued at approximately $8,640,656.64. The trade was a 1.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 11,401 shares of company stock worth $1,972,576. 7.00% of the stock is currently owned by corporate insiders.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.